Compare Fiverr International Ltd (FVRR) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fiverr International Ltd vs Novo Nordisk A/S — how do they compare? Fiverr International Ltd trades at $8.67 (market cap $314.57M), while Novo Nordisk A/S trades at $46.27 (market cap $207.85B). The key difference: Novo Nordisk A/S is far larger — about 660.7× Fiverr International Ltd's market cap, and Novo Nordisk A/S pays a 3.81% dividend while Fiverr International Ltd pays none. Which is the better fit depends on your goals.
| FVRR | NVO | |
|---|---|---|
Market Cap | $314.57M | $207.85B |
Sector | Industrials | Health |
52-Week High | $26.67 | $63.98 |
52-Week Low | $8.75 | $35.29 |
Enterprise Value | $66.95M | $222.55B |
Dividend Yield | — | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Fiverr International (FVRR) trades at $9.09, down 3.5% amid bearish technical signals and recent earnings misses. The stock shows attractive valuation metrics with P/E of 10.8 and P/S of 0.77, while revenue grew to $430.91M in 2025. However, Q2 2026 results disappointed with revenue declining 10% year-over-year as AI disruption pressures the freelance marketplace business model. Analyst sentiment remains cautious with 76% hold ratings despite a $10.70 consensus price target suggesting 18% upside potential.
Fiverr faces significant headwinds from AI competition compressing demand for lower-value freelance work, though current valuations appear discounted. The company maintains strong gross margins at 82% and positive net income, but growth sustainability concerns persist. Near-term catalysts include Q3 earnings and AI strategy execution, while risks center on market share erosion and guidance revisions. The stock trades near support levels with mixed technical indicators.
NVO trades at $47.73, up 0.99% today, with a neutral technical signal and strong fundamentals, including a P/E of 11.62 and net income margin of 35.35%. Recent Q2 2026 earnings beat expectations, but the stock faces mixed sentiment due to competitive pressures and pricing headwinds in its GLP-1 portfolio.
The outlook is cautiously optimistic, supported by robust profitability and analyst buy ratings (57.9%), but risks include intense competition from Eli Lilly and margin compression. Upside potential hinges on execution against guidance, while downside risks stem from market share erosion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fiverr International Ltd
Fiverr International Ltd is involved in buying and selling digital services in the same fashion as physical goods on an e-commerce platform. It is set out to design a digital marketplace that is built with a comprehensive SKU-like services catalog and a search, finds, and order process that mirrors a typical e-commerce transaction. The service offerings of the company include Graphics and Design, Digital Marketing, Writing and Translation, and Video and Animation among others.
Read more on FVRR →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
